Medtronic Inc. (NYSE:MDT) announced that it closed on PEAK Surgical Inc. and Salient Surgical Inc. for an aggregate $585 million.
The Minneapolis, Minn.-based med-tech giant paid $480 million for Salient and $105 million for PEAK, not considering Medtronic’s existing ownership stake.
PEAK brings in about $20 million in revenue annually and Salient adds approximately $100 million, according to a press release.
Medtronic announced in July that it would acquire Salient Surgical Technologies in a deal that’s been in the works for more than 11 years.
Previously known as TissueLink Medical, Portsmouth, N.H.-based Salient launched in August 1999, after securing an exclusive global license to "wet" electrode technology developed by Medtronic. The Fridley, Minn.-based device conglomerate has participated in each of Salient’s seven funding rounds over the last decade. In January, the company raised a final, $15 million round.
Both PEAK and Salient will operate under Medtronic’s restorative therapies group, which includes its spinal, neuromodulation, diabetes, and surgical technologies units. Those businesses pulled in nearly $16 billion in sales last year. The restorative therapies operation has come under intense pressure lately over the brewing Infuse bone growth controversy.
MDT stock was up 1 percent to $35.07 at the close of the day today.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.